{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:36:18Z","timestamp":1756384578798},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/bf02752281","type":"journal-article","created":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T07:16:20Z","timestamp":1201936580000},"page":"655-668","source":"Crossref","is-referenced-by-count":8,"title":["Systemic antifungal agents"],"prefix":"10.1007","volume":"68","author":[{"given":"Walid","family":"Abuhammour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyassu","family":"Habte-Gabr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02752281_CR1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/clinids\/20.3.571","volume":"20","author":"JK Stamos","year":"1995","unstructured":"Stamos JK, Rowley AH. Candidemia in a Pediatric Population.Clin Infect Dis 1995; 20: 571\u2013575.","journal-title":"Clin Infect Dis"},{"key":"BF02752281_CR2","first-page":"579","volume":"3","author":"W Gold","year":"1955\u20131956","unstructured":"Gold W, Stout NA, Pagano JF, Donovick R. Amphotericin A and B, Antifungal antibiotics produced by a streptomyces.In Vitro Studies.Antibiot Ann 1955\u20131956; 3: 579\u2013586.","journal-title":"Antibiot Ann"},{"key":"BF02752281_CR3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","volume":"12","author":"H Gallis","year":"1990","unstructured":"Gallis H, Drew R, Pickard W. Amphotericin B: 30 Years of Clinical Experience.Rev Infect Dis 1990; 12: 308\u2013329.","journal-title":"Rev Infect Dis"},{"key":"BF02752281_CR4","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1128\/AAC.34.7.1402","volume":"34","author":"EC Oldfield","year":"1990","unstructured":"Oldfield EC, Garst PD, Hostettler Cet al. Randomized, Double-blinded Trial of 1-versus-4 hour Amphotericin B Infusion Duration.Antimicrobial Agnets Chemother 1990; 34: 1402.","journal-title":"Antimicrobial Agnets Chemother"},{"key":"BF02752281_CR5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-2911(08)60307-0","volume":"27","author":"EF Gale","year":"1986","unstructured":"Gale EF. Nature and Development of Phenotypic Resistance to Amphotericin B in Candida Albicans.Adv Microb Physiol 1986; 27: 277\u2013319.","journal-title":"Adv Microb Physiol"},{"key":"BF02752281_CR6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0031-3955(16)38984-2","volume":"42","author":"GP DeMuri","year":"1995","unstructured":"DeMuri GP, Hostetter MK. Resistance to Antifungal Agents.Ped Clin of North America 1995; 42: 665\u2013685.","journal-title":"Ped Clin of North America"},{"key":"BF02752281_CR7","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.39.9.1907","volume":"39","author":"AM Sugar","year":"1995","unstructured":"Sugar AM. Use of Amphotericin B with Azole Antifungal Drugs: What Are We Doing?Antimicrob Agents Chemother 1995; 39: 1907.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02752281_CR8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198105143042001","volume":"304","author":"DG Wright","year":"1981","unstructured":"Wright DG, Robichavd J, Pizzo PA, Deisseroth AB. Lethal Pulmonary Reactions Associated with the Combined Use of Amphotericin B and Leukocyte Transfusions.N Engl J Med 1981; 304: 1185.","journal-title":"N Engl J Med"},{"key":"BF02752281_CR9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","volume":"40","author":"A Llanos","year":"1991","unstructured":"Llanos A, Ciezo, Bernado Jet al. Effect of Salt Supplementation on Emphotericin B Nephrotoxicity.Kidney Int 1991; 40: 302.","journal-title":"Kidney Int"},{"key":"BF02752281_CR10","unstructured":"Bennet JE. Antifungal Angets In Gilman AG, Rall TW, Nics AS, Taylor P, eds.The Pharmacological of Therapeutics. Maxwell, Macmillan Publishing Co. 1991; 1065\u20131073."},{"key":"BF02752281_CR11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","volume":"330","author":"JA Como","year":"1994","unstructured":"Como JA, Dismukes WE. Drug Therapy: Oral Azole Drugs as Systemic Antifungal Therapy.N Engl J Med 1994; 330: 263\u2013272.","journal-title":"N Engl J Med"},{"key":"BF02752281_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.32.1.1","volume":"32","author":"MS Saag","year":"1988","unstructured":"Saag MS, Dismukes WE. Azole Antifungal Agents: Emphasis on New Triazoles.Antimicrob Agents Chemother 1988; 32: 1\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02752281_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000238951","volume":"38","author":"HJ Schmirt","year":"1992","unstructured":"Schmirt HJ, Edwards F, Andrade J, Niki Y, Armstrong D. Comparison of Azoles Against Aspergilliin vitro and in Experimental Model of Pulmonary Aspergillosis.Chemotherapy 1992; 38: 118\u201326.","journal-title":"Chemotherapy"},{"key":"BF02752281_CR14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0891-5520(20)30531-6","volume":"7","author":"MA Pfaller","year":"1993","unstructured":"Pfaller MA, Rinaldi MG. Antifungal Susceptibility Testing. Current State of Technology, Limitations and Standardization.Infect Dis Clin North Am 1993; 7: 435\u2013444.","journal-title":"Infect Dis Clin North Am"},{"key":"BF02752281_CR15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","volume":"86","author":"JH Lewis","year":"1984","unstructured":"Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic Injury Associated with Ketoconazole Therapy: Analysis of 33 Cases.Gastroenterology 1984; 86: 503\u2013513.","journal-title":"Gastroenterology"},{"key":"BF02752281_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(93)90317-I","volume":"95","author":"JK Crane","year":"1993","unstructured":"Crane JK, Shih HT. Syncope and Cardiac Arrhythmias Due to Interaction Between Itraconazole and Terfenadine.Am J Med 1993; 95: 445\u2013446.","journal-title":"Am J Med"},{"key":"BF02752281_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-109-3-177","volume":"109","author":"WE Dismukes","year":"1988","unstructured":"Dismukes WE. Azole Anti-fungal Drugs: Old and New.Annals of Intern Medicine 1988; 109: 177\u2013179.","journal-title":"Annals of Intern Medicine"},{"key":"BF02752281_CR18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.32.3.369","volume":"32","author":"RM Tucker","year":"1988","unstructured":"Tucker RM, Williams PL, Arathoon EGet al. Pharmacokinetics of Fluconazole in Cerebrospinal Fluid and Serum in Human Coccidioidal Meningitis.Antimicrob Agents Chemother 1988; 32: 369\u2013373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"BF02752281_CR19","first-page":"5","volume":"12","author":"JD Lazar","year":"1990","unstructured":"Lazar JD, Wilner KD. Drug Interactions with Fluconazole.Rev Infect Dis 1990; 12 (suppl 3): 5 327\u2013333.","journal-title":"Rev Infect Dis"},{"key":"BF02752281_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/BF02730928","volume":"63","author":"PB Agrawal","year":"1996","unstructured":"Agrawal PB, Narang A, and Kumar P. Fluconazole.Indian J Pediatr 1996; 63: 775\u2013780.","journal-title":"Indian J Pediatr"},{"key":"BF02752281_CR21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199102283240902","volume":"324","author":"SA Bozzett","year":"1991","unstructured":"Bozzett SA, Larsen RA, Chiv Jet al. A Placebocontrolled Trial of Maintenance Therapy with Fluconazole After Treatment of Cryptococcal Meningitis in the Acquired Immunodeficiency Syndrome.N Engl J Med 1991; 324: 580\u2013584.","journal-title":"N Engl J Med"},{"key":"BF02752281_CR22","volume-title":"Principles and Practice of Pediatric Infectious Diseases","author":"SV Hetherington","year":"1997","unstructured":"Hetherington SV. Orlicek S. Patric C. Antifungal Agents. In Long SS, Pickering LK, Prober CG, eds.Principles and Practice of Pediatric Infectious Diseases. New York, Churchill Livingstone, 1997."},{"key":"BF02752281_CR23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","volume":"37","author":"JA Barone","year":"1993","unstructured":"Barone JA, Koh JG, Bierman RHet al. Food Interaction and Steady State Pharmacokinetics of Itraconazole Capsules in Healthy Male Volunteers.Antimicrob Agents Chemother 1993; 37: 778\u2013784.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF02752281_CR24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/clind\/16.3.400","volume":"16","author":"MK Sachs","year":"1993","unstructured":"Sachs MK, Blanchard LM, Green PJ. Interaction of Itraconazole and Digoxin.Clin Infect Dis 1993; 16: 400\u2013403.","journal-title":"Clin Infect Dis"},{"key":"BF02752281_CR25","first-page":"587","volume":"31","author":"DR Bikers","year":"1994","unstructured":"Bikers DR. Antifungal Therapy: Potential Interactions with Other Classes of Drugs.J Am Acad Dermatol 1994; 31: 587\u2013590.","journal-title":"J Am Acad Dermatol"},{"key":"BF02752281_CR26","first-page":"195","volume":"12","author":"Svarezs","year":"1997","unstructured":"Svarezs. New Antifungal Therapy for Children.Advances in Dermatology 1997; 12: 195\u2013209.","journal-title":"Advances in Dermatology"},{"key":"BF02752281_CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4065\/74.1.78","volume":"74","author":"C Terrell","year":"1999","unstructured":"Terrell C. Antifungal Agents, Part II, The Azoles.Mayo Clinic Proc 1999; 74: 78\u2013100.","journal-title":"Mayo Clinic Proc"},{"key":"BF02752281_CR28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","volume":"21","author":"A Polak","year":"1975","unstructured":"Polak A, Scholer HJ. Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance.Chemotherapy 1975; 21: 113.","journal-title":"Chemotherapy"},{"key":"BF02752281_CR29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1099\/00222615-6-3-315","volume":"6","author":"D Speller","year":"1973","unstructured":"Speller D, Davies M. Sensitivity of Yeasts to 5-Fluorocytosis.J Med Microbiol 1973; 6: 315\u2013321.","journal-title":"J Med Microbiol"},{"key":"BF02752281_CR30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","volume":"15","author":"P Francis","year":"1992","unstructured":"Francis P, Walsh T. Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics and Antifungal Therapy.Clin Infect Dis 1992; 15: 1003\u20131018.","journal-title":"Clin Infect Dis"},{"key":"BF02752281_CR31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0022-3476(88)80232-4","volume":"112","author":"RR Tanz","year":"1988","unstructured":"Tanz RR, Hebert AA, Esterly NB. Treating Tinea Capitis: Should Ketoconazole Replace Griseofulvin?J Pediatr 1988; 112: 987\u2013991.","journal-title":"J Pediatr"},{"key":"BF02752281_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0190-9622(94)70204-7","volume":"31","author":"L Frieden","year":"1994","unstructured":"Frieden L, Howard R. Tinea Capitis: Epidemiology, Diagnosis, Treatment and Control.J Am Acad Dermatol 1994; 31: 542\u2013546.","journal-title":"J Am Acad Dermatol"},{"key":"BF02752281_CR33","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1128\/AAC.42.12.3242","volume":"42","author":"F Macro","year":"1998","unstructured":"Macro F. p faller MA, Messerset al.In vitro activities of voriconazole (UK-109, 496) and four other antifungal agents against 394 clinical isolates of canidida spp.Antimicrobial Agents Chemotherapy 1998; 42: 3242\u20133244.","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"BF02752281_CR34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1369-5274(98)80087-8","volume":"1","author":"NH Georgopadakon","year":"1998","unstructured":"Georgopadakon NH. Antifungals: mechanism of action and resistance, established and novel drugs.Gurr Opin Microbial 1998; 1: 547\u2013557.","journal-title":"Gurr Opin Microbial"}],"container-title":["The Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02752281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02752281\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02752281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T07:49:31Z","timestamp":1630655371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02752281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["BF02752281"],"URL":"https:\/\/doi.org\/10.1007\/bf02752281","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}